| 52.21 |  -0.01 / -0.02% |
Data as of May 20 | Day’s Change |
| 52.20 | -0.01 / -0.02% |
Volume: 200.00 |
| Aveo Screwed Up but Its Kidney Cancer Drug Is Real May 15 / TheStreet.com | Glaxo/THRX's Breo Ellipta Gets FDA Nod - Analyst Blog May 13 / Zacks.com |
| Dirty Medicine May 15 / Fortune | Isis Reports In-Line Loss - Analyst Blog May 08 / Zacks.com |
| Elan in Royalty Deal with THRX - Analyst Blog May 14 / Zacks.com | Wider-than-Expected Loss at Dynavax - Analyst Blog May 07 / Zacks.com |
| Wider-than-Expected Loss at ChemoCentryx - Analyst Blog May 14 / Zacks.com | European drug stocks are on a tear Apr 24 / CNNMoney.com |
| GlaxoSmithKline PLC Stock Buy Recommendation Reiterated (GSK) May 14 / TheStreet.com | A new plan for creating new drugs Apr 23 / Fortune |
| Previous close | 52.22 |
| Today’s open | 52.19 |
| Day’s range | -- - -- |
| Volume | 1,411,396 |
| Average volume (3 months) | 2,746,601 |
| Market cap | $128.6B |
| Dividend yield | 4.49% |
| Earnings growth (last year) | -12.13% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +8.13% |
| Revenue growth (last year) | -4.52% |
| P/E ratio | -- |
| Price/Sales | 2.54 |
| Price/Book | 13.55 |
| Today’s change | Today’s % change | |
|---|---|---|
| MRKMerck & Co Inc | -0.78 | -1.70% |
| SNYSanofi SA | -0.66 | -1.21% |
| NVSNovartis AG | +0.01 | +0.01% |
| ABBVAbbVie Inc | -0.91 | -1.93% |
| Next reporting date | July 24, 2013 |
| EPS forecast (this quarter) | $0.84 |
| Annual revenue (last year) | $42.1B |
| Annual profit (last year) | $7.3B |
| Net profit margin | 17.27% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Andrew Philip Witty |
Chief Financial Officer & Executive Director Simon Dingemans |
Corporate headquarters Brentford, Greater London |
.
